Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators
{"title":"2020年撒哈拉以南非洲地区失明和视力障碍患病率:规模和时间趋势系统评价与元分析。","authors":"Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators","doi":"10.1080/09286586.2025.2474654","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess burden of blindness and visual impairment (VI) in Sub-Saharan Africa (SSA) as of 2020, the planned end point of the Vision 2020 program.</p><p><strong>Methods: </strong>A systematic review and meta-analysis assessed burden, in the better eye, of blindness (presenting distance visual acuity, VA < 3/60), moderate and severe vision impairment (MSVI; VA < 6/18 but ≥ 3/60) and mild vision impairment (VA < 6/12 and ≥ 6/18); and also functional presbyopia (<N6 or N8 in the presence of ≥ 6/12 best-corrected distance visual acuity) in SSA.</p><p><strong>Results: </strong>In 2020, an estimated 5,083,000 people (95%Uncertainty Interval, UI, 4,474,000-5,696,000) in SSA were bilaterally blind; 20442,000 more (95%UI 18,568,000-22,430,000) had MSVI. The age-standardized prevalence of blindness in SSA is the highest for any GBD super-region, nearly double the world average (0.99%, 95%UI, 0.85-1.12; vs 0.52%, 95% UI, 0.46-0.59 respectively). The Western (4.15%) and Eastern (3.79%) SSA sub-regions had the highest age-standardized prevalence of blindness for the 50+ age group amongst SSA sub-regions. Improvement in age-specific prevalence since 2000 was less than the Vision 2020 target (-25%) for all subcategories of VI; improvement in blindness was the only category close to the goal (about 80-100% of goal across SSA sub-regions).</p><p><strong>Conclusions: </strong>The SSA age-specific prevalence of VI has generally improved since 2000, especially for blindness. However, the number of VI cases has increased with population growth and aging, and Vision 2020 targets were not met. Because most causes of VI require individual-level clinical care, large increases in training and eye care delivery systems development/financing are critical areas of focus.</p>","PeriodicalId":19607,"journal":{"name":"Ophthalmic epidemiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of Blindness and Visual Impairment in Sub-Saharan Africa in 2020: Magnitude and Temporal Trends. Systematic Review and Meta-Analysis.\",\"authors\":\"Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators\",\"doi\":\"10.1080/09286586.2025.2474654\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To assess burden of blindness and visual impairment (VI) in Sub-Saharan Africa (SSA) as of 2020, the planned end point of the Vision 2020 program.</p><p><strong>Methods: </strong>A systematic review and meta-analysis assessed burden, in the better eye, of blindness (presenting distance visual acuity, VA < 3/60), moderate and severe vision impairment (MSVI; VA < 6/18 but ≥ 3/60) and mild vision impairment (VA < 6/12 and ≥ 6/18); and also functional presbyopia (<N6 or N8 in the presence of ≥ 6/12 best-corrected distance visual acuity) in SSA.</p><p><strong>Results: </strong>In 2020, an estimated 5,083,000 people (95%Uncertainty Interval, UI, 4,474,000-5,696,000) in SSA were bilaterally blind; 20442,000 more (95%UI 18,568,000-22,430,000) had MSVI. The age-standardized prevalence of blindness in SSA is the highest for any GBD super-region, nearly double the world average (0.99%, 95%UI, 0.85-1.12; vs 0.52%, 95% UI, 0.46-0.59 respectively). The Western (4.15%) and Eastern (3.79%) SSA sub-regions had the highest age-standardized prevalence of blindness for the 50+ age group amongst SSA sub-regions. Improvement in age-specific prevalence since 2000 was less than the Vision 2020 target (-25%) for all subcategories of VI; improvement in blindness was the only category close to the goal (about 80-100% of goal across SSA sub-regions).</p><p><strong>Conclusions: </strong>The SSA age-specific prevalence of VI has generally improved since 2000, especially for blindness. However, the number of VI cases has increased with population growth and aging, and Vision 2020 targets were not met. Because most causes of VI require individual-level clinical care, large increases in training and eye care delivery systems development/financing are critical areas of focus.</p>\",\"PeriodicalId\":19607,\"journal\":{\"name\":\"Ophthalmic epidemiology\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09286586.2025.2474654\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09286586.2025.2474654","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Prevalence of Blindness and Visual Impairment in Sub-Saharan Africa in 2020: Magnitude and Temporal Trends. Systematic Review and Meta-Analysis.
Purpose: To assess burden of blindness and visual impairment (VI) in Sub-Saharan Africa (SSA) as of 2020, the planned end point of the Vision 2020 program.
Methods: A systematic review and meta-analysis assessed burden, in the better eye, of blindness (presenting distance visual acuity, VA < 3/60), moderate and severe vision impairment (MSVI; VA < 6/18 but ≥ 3/60) and mild vision impairment (VA < 6/12 and ≥ 6/18); and also functional presbyopia (
Results: In 2020, an estimated 5,083,000 people (95%Uncertainty Interval, UI, 4,474,000-5,696,000) in SSA were bilaterally blind; 20442,000 more (95%UI 18,568,000-22,430,000) had MSVI. The age-standardized prevalence of blindness in SSA is the highest for any GBD super-region, nearly double the world average (0.99%, 95%UI, 0.85-1.12; vs 0.52%, 95% UI, 0.46-0.59 respectively). The Western (4.15%) and Eastern (3.79%) SSA sub-regions had the highest age-standardized prevalence of blindness for the 50+ age group amongst SSA sub-regions. Improvement in age-specific prevalence since 2000 was less than the Vision 2020 target (-25%) for all subcategories of VI; improvement in blindness was the only category close to the goal (about 80-100% of goal across SSA sub-regions).
Conclusions: The SSA age-specific prevalence of VI has generally improved since 2000, especially for blindness. However, the number of VI cases has increased with population growth and aging, and Vision 2020 targets were not met. Because most causes of VI require individual-level clinical care, large increases in training and eye care delivery systems development/financing are critical areas of focus.
期刊介绍:
Ophthalmic Epidemiology is dedicated to the publication of original research into eye and vision health in the fields of epidemiology, public health and the prevention of blindness. Ophthalmic Epidemiology publishes editorials, original research reports, systematic reviews and meta-analysis articles, brief communications and letters to the editor on all subjects related to ophthalmic epidemiology. A broad range of topics is suitable, such as: evaluating the risk of ocular diseases, general and specific study designs, screening program implementation and evaluation, eye health care access, delivery and outcomes, therapeutic efficacy or effectiveness, disease prognosis and quality of life, cost-benefit analysis, biostatistical theory and risk factor analysis. We are looking to expand our engagement with reports of international interest, including those regarding problems affecting developing countries, although reports from all over the world potentially are suitable. Clinical case reports, small case series (not enough for a cohort analysis) articles and animal research reports are not appropriate for this journal.